Results 301 to 310 of about 222,357 (321)
Some of the next articles are maybe not open access.
Immunomodulation for glioblastoma
Current Opinion in Neurology, 2017Purpose of review Immunotherapy has emerged as a cornerstone of modern oncology with regulatory approvals for a variety of immunotherapeutics being achieved for a spectrum of cancer indications. Nonetheless the role of these approaches for patients with glioblastoma (GBM), the most common and deadliest primary malignant brain ...
John H. Sampson +3 more
openaire +3 more sources
Journal of Neurosurgery, 1981
✓ The results of a second operation for tumor removal in 24 adult patients with supratentorial glioblastoma multiforme or anaplastic astrocytoma were analyzed. The median survival time after reoperation was 14 weeks. Five of the 24 patients lived 6 months or longer after reoperation. Only three of these patients maintained a Karnofsky rating (KR) of at
Phillip A. Tibbs +8 more
openaire +3 more sources
✓ The results of a second operation for tumor removal in 24 adult patients with supratentorial glioblastoma multiforme or anaplastic astrocytoma were analyzed. The median survival time after reoperation was 14 weeks. Five of the 24 patients lived 6 months or longer after reoperation. Only three of these patients maintained a Karnofsky rating (KR) of at
Phillip A. Tibbs +8 more
openaire +3 more sources
World Neurosurgery, 2018
Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor ...
Jessica A. Wilcox +2 more
openaire +2 more sources
Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor ...
Jessica A. Wilcox +2 more
openaire +2 more sources
Pediatric Pathology, 1985
Both morphologic and clinical features of 72 consecutive cases of brain tumors, collected over 9 years at Le Bonheur Children's Medical Center, were reviewed. We identified 11 cases as glioblastoma, representing 16% of all intracranial neoplasm and 26% of glial tumors. The patients ranged in age from 1 to 15 years with the median age of 10 years. There
Suk-Jung Koh +2 more
openaire +3 more sources
Both morphologic and clinical features of 72 consecutive cases of brain tumors, collected over 9 years at Le Bonheur Children's Medical Center, were reviewed. We identified 11 cases as glioblastoma, representing 16% of all intracranial neoplasm and 26% of glial tumors. The patients ranged in age from 1 to 15 years with the median age of 10 years. There
Suk-Jung Koh +2 more
openaire +3 more sources
Acta Oncologica, 2009
Glioblastomas are considered fast-growing tumors, but there is little information on their growth kinetics prior to diagnosis.
Hofer, S, Kollias, S, Weller, M
openaire +3 more sources
Glioblastomas are considered fast-growing tumors, but there is little information on their growth kinetics prior to diagnosis.
Hofer, S, Kollias, S, Weller, M
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2007
Glioblastoma multiforme (GBM) are among the most devastating neoplasms claiming the lives of patients within a median of 1 year after diagnosis. Treatment of GBM requires a multidisciplinary approach. Treatments include surgery, radiotherapy, chemotherapy and so on. Temozolomide (TMZ) has emerged as an active agent against malignant gliomas.
Tomokazu Aoki +2 more
openaire +3 more sources
Glioblastoma multiforme (GBM) are among the most devastating neoplasms claiming the lives of patients within a median of 1 year after diagnosis. Treatment of GBM requires a multidisciplinary approach. Treatments include surgery, radiotherapy, chemotherapy and so on. Temozolomide (TMZ) has emerged as an active agent against malignant gliomas.
Tomokazu Aoki +2 more
openaire +3 more sources
Chemoradiation for Glioblastoma
Current Drug Therapy, 2010Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Until recently, the standard of care consisted of maximal surgical resection followed by external beam radiotherapy (RT). Several randomized trials conducted over the past 30 years have failed to show a significant survival advantage for patients treated with BCNU or PCV ...
Minniti G. +3 more
openaire +3 more sources
Current Treatment Options in Neurology, 2008
Patients with newly diagnosed glioblastoma multiforme should undergo a maximal tumor resection and then, whenever possible, should be entered into a clinical trial. The current standard of care consists of external beam irradiation, to a total of 60 Gy over 6 weeks, in combination with low-dose daily temozolomide, followed by at least six cycles of ...
openaire +3 more sources
Patients with newly diagnosed glioblastoma multiforme should undergo a maximal tumor resection and then, whenever possible, should be entered into a clinical trial. The current standard of care consists of external beam irradiation, to a total of 60 Gy over 6 weeks, in combination with low-dose daily temozolomide, followed by at least six cycles of ...
openaire +3 more sources
Current Treatment Options in Neurology, 2009
Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide.
Rose Lai, Mary Welch
openaire +3 more sources
Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide.
Rose Lai, Mary Welch
openaire +3 more sources
Gériatrie et Psychologie Neuropsychiatrie du Viellissement, 2011
The incidence of malignant gliomas is growing in the elderly population. Unfortunately, increasing age is one of the most important negative prognostic factors for gliomas, and the optimal management of this population remains largely unsettled because older patients are often excluded from clinical trials.
Florence Laigle-Donadey +1 more
openaire +3 more sources
The incidence of malignant gliomas is growing in the elderly population. Unfortunately, increasing age is one of the most important negative prognostic factors for gliomas, and the optimal management of this population remains largely unsettled because older patients are often excluded from clinical trials.
Florence Laigle-Donadey +1 more
openaire +3 more sources